MyAverix Finance MyAverix Finance

US

Drugs Made In America Acquisition Corp. Rights (DMAAR)

Drugs Made In America Acquisition Corp. Rights (DMAAR) is listed on US. As of 2026-03-24, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Data as of 2026-03-24

Download on the App Store Get it on Google Play

Download free on iPhone and Android

Key metrics for DMAAR

P/E ratio
18.00

Drugs Made In America Acquisition Corp. Rights (DMAAR) — FAQ

What is DMAAR's P/E ratio?

The price-to-earnings (P/E) ratio for Drugs Made In America Acquisition Corp. Rights (DMAAR) is 18.00 (data as of 2026-03-24).

Does Drugs Made In America Acquisition Corp. Rights pay a dividend?

Dividend yield is not available in the current snapshot for Drugs Made In America Acquisition Corp. Rights (DMAAR). Check the MyAverix Finance app for the latest dividend data.

What exchange is DMAAR listed on?

DMAAR is listed on US.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

← All stocks

MyAverix Finance provides company information and financial data for educational and research purposes only. We are not a broker, advisor, or investment service. Data may be delayed or incomplete. Past performance does not guarantee future results. Always do your own research before making financial decisions.

Terms of Use

App Store Google Play